表型易感性的转变表明在一例对马拉维若产生获得性耐药的病例中存在竞争机制。 - Suppr

Shift in phenotypic susceptibility suggests a competition mechanism in a case of acquired resistance to maraviroc.

作者信息

Delobel Pierre, Raymond Stéphanie, Mavigner Maud, Cazabat Michelle, Alvarez Muriel, Marchou Bruno, Massip Patrice, Izopet Jacques

出版信息

AIDS. 2010 Jun 1;24(9):1382-4. doi: 10.1097/QAD.0b013e328338b7a6.

DOI:10.1097/QAD.0b013e328338b7a6

PMID:20559045

Abstract

摘要

相似文献

Shift in phenotypic susceptibility suggests a competition mechanism in a case of acquired resistance to maraviroc.

AIDS. 2010 Jun 1;24(9):1382-4. doi: 10.1097/QAD.0b013e328338b7a6.

[Pretreated HIV patients profit from Maraviroc. Oral HIV fusion inhibitor opens new therapy chances].

MMW Fortschr Med. 2008 Apr 28;150 Spec No 1:52-3.

Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.

Antivir Ther. 2011;16(3):395-404. doi: 10.3851/IMP1759.

When and how to use maraviroc in HIV-infected patients.

AIDS. 2009 Nov 27;23(18):2377-85. doi: 10.1097/QAD.0b013e328332d32d.

Anti-HIV agents. Maraviroc and resistance.

TreatmentUpdate. 2007 Sep-Oct;19(6):4-5.

Antiviral effect of maraviroc in semen: a case report.

Antivir Ther. 2012;17(5):933-6. doi: 10.3851/IMP2038. Epub 2012 Feb 1.

Two new drugs for HIV infection.

Med Lett Drugs Ther. 2008 Jan 14;50(1277):2-4.

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.

J Virol. 2007 Mar;81(5):2359-71. doi: 10.1128/JVI.02006-06. Epub 2006 Dec 20.

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients.

Drug Des Devel Ther. 2016 Jan 18;10:353-4. doi: 10.2147/DDDT.S100639. eCollection 2016.

Concurrent use of statins does not influence efficacy of maraviroc in Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients 1 and 2 trials.

AIDS. 2009 Jul 31;23(12):1613. doi: 10.1097/QAD.0b013e32832dbfa7.

引用本文的文献

V1 and V2 Domains of HIV Envelope Contribute to CCR5 Antagonist Resistance.

J Virol. 2019 Apr 17;93(9). doi: 10.1128/JVI.00050-19. Print 2019 May 1.

Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies.

Antimicrob Agents Chemother. 2015 Nov 2;60(1):437-50. doi: 10.1128/AAC.02285-15. Print 2016 Jan.

V3-independent competitive resistance of a dual-X4 HIV-1 to the CXCR4 inhibitor AMD3100.

PLoS One. 2014 Feb 19;9(2):e89515. doi: 10.1371/journal.pone.0089515. eCollection 2014.

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.

Retrovirology. 2013 Apr 20;10:43. doi: 10.1186/1742-4690-10-43.

Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.

J Virol. 2012 Jun;86(12):6416-26. doi: 10.1128/JVI.00286-12. Epub 2012 Apr 4.

HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.

J Virol. 2012 Jan;86(2):1119-28. doi: 10.1128/JVI.06421-11. Epub 2011 Nov 16.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Shift in phenotypic susceptibility suggests a competition mechanism in a case of acquired resistance to maraviroc.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献